An Impossible Balance: Antibiotic Resistance, Profits, and Public Health

DSpace/Manakin Repository

An Impossible Balance: Antibiotic Resistance, Profits, and Public Health

Show simple item record

dc.contributor.advisor Peter Hutt en_US
dc.contributor.author Barella, Nigel
dc.date.accessioned 2012-06-07T01:54:18Z
dc.date.issued 2011
dc.identifier.citation Nigel Barella, An Impossible Balance: Antibiotic Resistance, Profits, and Public Health (May 2011) en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846728
dc.description.abstract The scientific mechanism for the development of antibiotic resistance in microbes has long been understood, and has long cautioned against the use of low doses of antibiotics insufficient to treat disease thoroughly. Despite this, low doses of antibiotics have, for nearly half a century, been given to food animals to promote faster growth and greater feed efficiency. Though this raises public health concerns, a complex political landscape has historically prevented these public health concerns from dominating regulatory policy, and continues to do so. This paper examines the scientific, political, and legal issues associated with the use of antibiotics in animal agriculture, with particular focus on FDA’s historical and evolving role in regulating this issue, and concludes briefly with speculation about the future of this issue. en_US
dash.license LAA
dc.subject.other Food and Drug Law en_US
dc.title An Impossible Balance: Antibiotic Resistance, Profits, and Public Health en_US
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T01:54:18Z

Files in this item

Files Size Format View
Barrella_Impossible_Balance[1].pdf 226.3Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters